AMGEN Inc
NASDAQ: AMGN
$283.61
-$12.32 (-4.2%)
Closing Price on November 15, 2024
AMGN Articles
24/7 Wall St. has reviewed the short interest data on the top biotech companies.
Published:
Last Updated:
The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.
Published:
Last Updated:
ThinkstockAmgen Inc. (NASDAQ: AMGN) released its third quarter earnings report Wednesday after the markets closed. The biotech giant had $2.72 in earnings per share (EPS) on $5.72 billion in revenue...
Published:
Last Updated:
Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.
Published:
The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
Published:
Amgen is slowly getting closer to an FDA final decision for its first-of-a-kind cancer therapy, talimogene laherparepvec (T-Vec).
Published:
Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech now.
Published:
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.
Published:
Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.
Published:
Independent research firm Argus has reviews of three of health care picks from its own Focus List in which it still sees significant upside ahead.
Published:
24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a single tweet did to them last week.
Published:
The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.
Published:
According to Fitch Ratings, biosimilars are beginning to take share from their reference biologics. This is seen in the debut of the first biosimilar drug in the United States.
Published:
Amgen and Xencor have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.
Published:
The short interest data are out for the August 31 settlement date. Short interest in the selected biotech stocks increased across the board for this settlement date.
Published: